These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

862 related items for PubMed ID: 27133890

  • 1. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    De Clercq E.
    Biochem Pharmacol; 2016 Nov 01; 119():1-7. PubMed ID: 27133890
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
    Okochi H, Louie A, Phung N, Zhang K, Tallerico RM, Kuncze K, Spinelli MA, Koss CA, Benet LZ, Gandhi M.
    Drug Test Anal; 2021 Jul 01; 13(7):1354-1370. PubMed ID: 33742745
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
    Imaz A, Niubó J, Cottrell ML, Perez E, Kashuba ADM, Tiraboschi JM, Morenilla S, Garcia B, Podzamczer D.
    Clin Infect Dis; 2019 Sep 27; 69(8):1403-1409. PubMed ID: 30561517
    [Abstract] [Full Text] [Related]

  • 8. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Mena-De-Cea Á, López-Calvo S, Vázquez-Rodríguez P, Martín-Herranz I, Míguez-Rey E, Poveda E, Castro-Iglesias Á.
    Basic Clin Pharmacol Toxicol; 2019 Apr 27; 124(4):479-490. PubMed ID: 30388308
    [Abstract] [Full Text] [Related]

  • 9. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
    DeJesus E, Haas B, Segal-Maurer S, Ramgopal MN, Mills A, Margot N, Liu YP, Makadzange T, McCallister S.
    AIDS Res Hum Retroviruses; 2018 Apr 27; 34(4):337-342. PubMed ID: 29368537
    [Abstract] [Full Text] [Related]

  • 10. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
    Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Kido A, Jiang S, Kulkarni R, Cheng A, Cao H.
    J Acquir Immune Defic Syndr; 2018 Jun 01; 78(2):209-213. PubMed ID: 29481486
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
    Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, DeJesus E, Clarke AE, Guo S, Wang H, Callebaut C, Plummer A, Cheng A, Das M, McCallister S.
    J Acquir Immune Defic Syndr; 2017 Jun 01; 75(2):211-218. PubMed ID: 28282300
    [Abstract] [Full Text] [Related]

  • 13. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.
    Bonora S, Calcagno A, Trentalange A, Di Perri G.
    Expert Opin Pharmacother; 2016 Jun 01; 17(3):409-19. PubMed ID: 26642079
    [Abstract] [Full Text] [Related]

  • 14. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
    Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD.
    Ann Intern Med; 2020 May 05; 172(9):583-590. PubMed ID: 32150602
    [Abstract] [Full Text] [Related]

  • 15. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
    Angione SA, Cherian SM, Özdener AE.
    J Pharm Pract; 2018 Apr 05; 31(2):216-221. PubMed ID: 28558493
    [Abstract] [Full Text] [Related]

  • 16. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.
    Maggiolo F, Rizzardini G, Raffi F, Pulido F, Mateo-Garcia MG, Molina JM, Ong E, Shao Y, Piontkowsky D, Das M, McNicholl I, Haubrich R.
    Lancet HIV; 2019 Oct 05; 6(10):e655-e666. PubMed ID: 31578954
    [Abstract] [Full Text] [Related]

  • 17. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
    Imaz A, Podzamczer D.
    Expert Rev Anti Infect Ther; 2017 Mar 05; 15(3):195-209. PubMed ID: 28117606
    [Abstract] [Full Text] [Related]

  • 18. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
    Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V, Jezorwski J, Petrovic R, Brown K, Van Landuyt E, Opsomer M, EMERALD study group.
    Antiviral Res; 2019 Oct 05; 170():104543. PubMed ID: 31279073
    [Abstract] [Full Text] [Related]

  • 19. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Podany AT, Bares SH, Havens J, Dyavar SR, O'Neill J, Lee S, Fletcher CV, Swindells S, Scarsi KK.
    AIDS; 2018 Mar 27; 32(6):761-765. PubMed ID: 29334548
    [Abstract] [Full Text] [Related]

  • 20. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo AB, Westmoreland DA, Carneiro PB, Johnson J, Grov C.
    AIDS Patient Care STDS; 2021 Aug 27; 35(8):327-334. PubMed ID: 34375141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.